Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) is now available.
AIM Vaccine Co., Ltd. announced a significant decrease in net loss for the year ending December 31, 2024, with unaudited net losses expected to range from RMB250 million to RMB290 million, representing an 85% to 87% reduction compared to the previous year. This improvement is attributed to increased revenue from HBV vaccinations and reduced asset impairment losses, signaling a positive shift in the company’s financial health and operational efficiency.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry with a focus on vaccine development and production. The company primarily generates revenue through its HBV vaccination products.
YTD Price Performance: -42.67%
Average Trading Volume: 6,171,710
Technical Sentiment Consensus Rating: Buy
For detailed information about 6660 stock, go to TipRanks’ Stock Analysis page.